A current weight-loss and diabetes drug has become a surprise candidate for migraine treatment, with a new pilot study showing the GLP-1 receptor agonist provided

I generally don’t like to buy stocks that are in downtrends. You just never know when the trend is going to end. Yet recently, the

Several incretin hormone therapies have been clinically approved and have revolutionized the treatment of diabetes and obesity. Promising therapeutics include semaglutide (Ozempic and Wegovy), an

Abstract Aims To evaluate the cost-effectiveness of liraglutide, semaglutide, tirzepatide, benaglutide, and lifestyle management for the treatment of obesity from the perspective of the Chinese

Kidess et al. present a timely meta-analysis suggesting that sodium–glucose cotransporter-2 inhibitors (SGLT2i) reduce the risk of new-onset atrial fibrillation (AF) compared to GLP-1 receptor

Novo Nordisk NVO has experienced remarkable growth in recent years, largely fueled by the commercial success of its blockbuster semaglutide (GLP-1 RA)-based therapies, Wegovy for obesity

I’m looking for good information on how to increase GLP-1 levels in a patient with pituitary insufficiency without using sub-Q injections like Ozempic. Any information

(NewsNation) — Ultraprocessed foods engineered with fat, sugar and salt are “addictive” and driving America’s obesity crisis, according to a former Food and Drug Administration

Improving access and affordability could be transformative for public health, given that about 88% of Americans are metabolically unhealthy.

AI is projected to generate over $350B in annual value for the pharmaceutical sector, as mounting cost pressures and looming revenue losses (pharma companies face

The STRIDE trial has laid the foundation for a paradigm shift in how we use GLP-1 RAs for symptomatic peripheral arterial disease. Medscape Diabetes &

People taking glucagon-like peptide-1 (GLP-1) receptor agonists had a higher risk of neovascular age-related macular degeneration (nAMD) in a retrospective study, which built on previous

Last week, many media outlets reported on a press release from the UK Medicines and Healthcare products Regulatory Agency (MHRA). It sought the collaboration of

It is a truth universally acknowledged that a biotech in possession of a mid-stage GLP-1 must be in want of a partner. Structure Therapeutics is

Source: APA Monitor At first, Meghan Dressler wasn’t interested in taking a glucagon-like peptide-1 (GLP-1) receptor agonist, the class of popular diabetes and weight-loss medications

Image Credit: NovoCare Pharmacy What You Should Know: – WeightWatchers, the global leader in science-backed weight management, announced a expansion of its collaboration with Novo

Beyond diabetes control and weight management, GLP-1s could have yet another benefit: helping with migraines. In a small study, a GLP-1 drug shrank the number

Facing tighter margins in the healthcare sector, Cambridge, Mass.-based Beth Israel Lahey Health is doubling down on direct-to-employer offerings to shore up revenue.  The 14-hospital

New rules are reshaping the telehealth market for GLP-1s like Ozempic and Wegovy. Here’s what to know going forward.

This systematic review and meta-analysis examines data for patients with diabetes and/or obesity from trials of GLP1-RA treatment to evaluate psychiatric, cognitive, and quality-of-life outcomes

Protagonist Therapeutics Inc. has nominated PN-477 as a development candidate for the treatment of obesity.

Hello, everyone, and how are you today? We are doing just fine, thank you, especially since the middle of the week is already upon us.

Biocon Ltd is expected to be the first to launch a semaglutide copycat drug in Canada. (Upstox pic) BENGALURU: Biocon Ltd plans to file for

Could China’s New GLP-1 Drugs Beat Out Ozempic?  Scientific American

As GLP-1 medications including Wegovy, Ozempic, Mounjaro and Zepbound reshape diabetes and weight loss care, recent developments such as new partnerships, safety questions and challenges

Innovent Biologics Inc. announced June 27 that it gained National Medical Products Administration’s (NMPA) approval of mazdutide as a new weight loss therapy for obese

(MedPage Today) — Over 60% of patients who started semaglutide (Wegovy) for obesity were still taking it a year later; but only one in seven

The US Food and Drug Administration (FDA) recently accepted a new drug application for oral semaglutide. If approved, it would be the first oral glucagon-like

Metabolic dysfunction–associated steatohepatitis (MASH), the progressive inflammatory form of MASLD, is now a leading cause of chronic liver disease worldwide. Driven by obesity and type

A GLP-1 drug led to fewer days with headaches, a small pilot study of migraine sufferers shows. It may work by lowering pressure inside the

The drug helped people who couldn’t get relief from existing treatments. It starts with flashes of light. Zig-zag lines float across your vision. You feel

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver disease and type 2 diabetes

Top of the morning to you. And a steamy one, it is. In fact, there is more steam rising from the grounds of the Pharmalot

WEIGHT loss, warding off dementia, ‘curing’ diabetes and now… anti-ageing powers? Is there anything the so-called fat jabs can’t do? ShutterstockVarious studies have found that Ozempic-like fat